

# CDER Office of Compliance Drug Shortage Overview

*Silvia Wanis, PharmD., MS, BCPPS, CPH, RAC  
CDR, U.S. Public Health Service  
Senior Regulatory Officer  
Incidents, Recalls, and Shortages Branch  
Division of Supply Chain Integrity  
Office of Drug Security, Integrity, and Response  
Office of Compliance  
Center for Drug Evaluation and Research*

# OBJECTIVES

- Discuss CDER Office of Compliance's Mission, Organizational Structure, and Role.
- Define CDER's Multidisciplinary Drug Shortage Mitigation Process.
- Describe Interagency Coordination Efforts between Office of Compliance and the Drug Shortage Staff.
- Provide Key Recommendations.

## Who We Are




### **CDER Office of Compliance Mission:**

To shield the public from poor quality, unsafe, and ineffective drugs through proactive compliance strategies and risk-based enforcement actions.

### **Incidents, Recalls, and Shortages Branch Role:**

Evaluation and classification of drug recalls; FDA's point of contact for and support to the Drug Shortage Staff by coordinating all CDER Office of Compliance program actions for management of a drug shortage.


# Drug Shortage Mitigation: A Multidisciplinary Approach



# Drug Shortage Mitigation

- Incoming shortage proposals from Industry:  
Incidents, Recalls and Shortages Branch (IRSB) consolidates CDER Office of Compliance (OC) recommendations and provides OC's position to a firm's shortage proposal to the Drug Shortage Staff (DSS).
- Outgoing shortage evaluations from Office of Compliance to Drug Shortage Staff:  
IRSB communicates CDER OC considerations to DSS prior to issuance of a Warning Letter or taking any enforcement action.
- Proactive Recall notifications to the Drug Shortage Staff

# Drug Shortage Mitigation: A Multidisciplinary Approach



# Key Recommendations



## Promote Voluntary Compliance

*Adhere to the Food, Drug, and Cosmetics Act*



## Ensure Adequate Investigation

*Thoroughly analyze root cause of shortage*



## Provide a Realistic Timeline

*Outline a timeline for investigating product defects and scheduling restarts after shutdowns*



## Anticipate Potential Issues and Maintain Frequent Communication

*Identify risks that could lead to shortages early  
Ensure up-to-date knowledge of CMO processes and facilities*

# Key Recommendations



## Consult with FDA Field Offices

*Reach out for guidance on potential recalls*



## Build Robust Inventories

*Prior to major manufacturing changes (e.g., facility upgrades or ownership transfers)*



## Provide Short-Long-Term Proposals

*Address potential shortage issues in notifications to the FDA*



## Engage in Dialogue with FDA

*Collaborate on long-term solutions and remediation efforts*





**U.S. FOOD & DRUG**  
ADMINISTRATION